Of the 35 biopsies performed, 18 (51%) indicated the presence of cancer and were in 13 (4%) of 305 MSH2 carriers, four (3%) of 135 MSH6 carriers, and one (<1%) of 210 MSH2 non-carrier controls. Here, MSH6 is linked to cancer.